Roger Lane

Roger Lane is the VP of Clinical Development at Ionis Pharmaceuticals. Roger has over 20 years of experience in the pharmaceutical industry, having worked at Bristol-Myers Squibb, Novartis Pharmaceutical, and Pfizer. Roger is a global expert in clinical development, with a focus on neuroscience and mental health. Roger has played a pivotal role in the development of several novel antidepressants and antipsychotics, including agomelatine, Fanapt, and ATI355. Roger is a passionate advocate for improved access to mental health care and is committed to making progress in this area through their work at Ionis Pharmaceuticals.

After completing their MPH at Columbia University, Roger Lane worked as a doctor in the public health field. Roger then went on to earn their MD at the University of Bristol. Roger is currently a doctor at King's School in Worcester.

Some of their coworkers include Michael McCaleb - VP, Clinical Development, Ken Newman - VP, Clinical Development. Roger Lane reports to Eugene Schneider, Executive Vice President, Chief Clinical Development Officer.